Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 12

recruiting
3 972
countries
28
conditions
2 103

467 trials match your criteria

Colorectal cancer metastatic

Recruiting

Study on Personalized Treatment for Metastatic Colorectal Cancer Using Methotrexate and Drug Combination for Patients with Advanced Disease

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Alectinib

Penile cancer

Recruiting

Study on the Effectiveness of Carboplatin, Paclitaxel, and Pembrolizumab for Patients with Advanced Penile Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Non-small cell lung cancer

Recruiting

Study on the Safety and Effectiveness of Nivolumab, Pembrolizumab, and Cemiplimab with Radiotherapy for Stage IV Non-Small Cell Lung Cancer Patients

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab

Malignant fibrous histiocytoma+1

Recruiting

Study on Propranolol and Pembrolizumab for Patients with Advanced Angiosarcoma and Undifferentiated Pleomorphic Sarcoma

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab

Non-small cell lung cancer+1

Recruiting

Study on the Safety and Effects of Divarasib with Pembrolizumab and a Drug Combination for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with KRAS G12C Mutation

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Budesonide

Breast cancer+2

Recruiting

Study on Pembrolizumab and Paclitaxel for Early Triple-Negative Breast Cancer in Patients with High Tumor-Infiltrating Lymphocytes

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Paclitaxel

Squamous cell carcinoma of head and neck

Recruiting

Study of Amivantamab, Pembrolizumab, and Paclitaxel for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab

Non-small cell lung cancer

Recruiting

Study of MK-1084 and Pembrolizumab for First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer with KRAS G12C Mutation and High PD-L1 Levels

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:MK-1084

Triple negative breast cancer

Recruiting

Study of Sacituzumab Tirumotecan and Pembrolizumab for Patients with Triple-Negative Breast Cancer Post-Surgery

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine

Non-small cell lung cancer

Recruiting

Study of RMC-6291 and Pembrolizumab with or without Chemotherapy for Patients with Advanced KRAS G12C Mutated Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Non-small cell lung cancer

Recruiting

Study to Compare Datopotamab Deruxtecan with Rilvegostomig or Alone Against Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with High PD-L1 Levels

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Infliximab

Neoplasm

Recruiting

Study of MDNA11 Alone or with Pembrolizumab for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:IrelandIreland
  • Participants:18–64 years · 65+ years
  • Substances:MDNA11

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.